English Archives - Page 2 of 7 - EMEA

This site provides INTERCEPT product information for International audiences .

Case study: enabling double dose methodology on Reveos through pathogen inactivation

Case study: enabling double dose methodology on Reveos through pathogen inactivation

by jaycornell | May 6, 2025

Ms. Eleonore Tennby Cerus Europe B.V. Amersfoort, the Netherlands

Cryoprecipitate from pathogen reduced concurrent apheresis plasma

Cryoprecipitate from pathogen reduced concurrent apheresis plasma

by jaycornell | May 5, 2025

Dr. Konrad Rosskopf, MD Medical University Graz Graz, Austria

Production and in vitro quality of pooled whole blood derived PI plasma

Production and in vitro quality of pooled whole blood derived PI plasma

by jaycornell | May 5, 2025

Dr. sc. nat. David Goslings, MBA Blood Transfusion Service Zurich Zurich, Switzerland

How pools-of-pools contributes to optimising your PI platelet products

How pools-of-pools contributes to optimising your PI platelet products

by jaycornell | May 5, 2025

Mr. Jean-Marc Payrat Cerus Europe B.V. Amersfoort, the Netherlands

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System

by jaycornell | May 5, 2025

Dr. Mohammad R. Abedi, MD, PhD Örebro University Hospital Stockholm, Sweden

« Older Entries

Next Entries »